论文部分内容阅读
2008年9月4日,Antisoma公司宣布开始AS1411治疗转移性肾癌的Ⅱ期临床试验。AS1411是一种表达于癌细胞表面的蛋白,是结合于核仁的寡核苷酸实体。试验将招募30名患者,接受至少两次为期4天的治疗(40mg.(kg.d)-1,每次治疗间隔为28天)来评估AS1411单一治疗转移性肾癌的有效性和安全
September 4, 2008, Antisoma Corporation announced the start of AS1411 treatment of metastatic renal cell carcinoma in Phase II clinical trials. AS1411 is a protein expressed on the surface of cancer cells and is an oligonucleotide entity that binds to the nucleolus. The trial will enlist 30 patients for at least two 4-day treatments (40 mg. (Kg · d -1) for 28 days at each treatment interval) to assess the efficacy and safety of AS1411 monotherapy in the treatment of metastatic renal cell carcinoma